deltatrials
Completed PHASE3 NCT00363896

A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)

Clinical Trial Assessing Efficacy and Safety of LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD) Patients

Sponsor: AstraZeneca

Conditions Chronic Obstructive Pulmonary Disease (COPD)
Interventions Aclidinium bromide Placebo
Updated 6 times since 2017 Last updated: Nov 16, 2016 Started: Jul 31, 2006 Primary completion: May 31, 2008 Completion: May 31, 2008

Listed as NCT00363896, this PHASE3 trial focuses on Chronic Obstructive Pulmonary Disease (COPD) and remains completed. Sponsored by AstraZeneca, it has been updated 6 times since 2006, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

6 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 1 earlier version

  1. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Jul 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • AstraZeneca
Data source: AstraZeneca

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Aalborg, Denmark, Aalst, Belgium, Bad Wörishofen, Germany, Badalona, Spain, Barcelona, Spain, Bedford, United Kingdom, Berlin, Germany, Berlin-Spandau, Germany, Beuvry, France, Bonn, Germany and 87 more location s